Matsuzaki T
Yakult Central Institute for Microbiological Research, Tokyo, Japan.
Int J Food Microbiol. 1998 May 26;41(2):133-40. doi: 10.1016/s0168-1605(98)00046-4.
Lactobacillus casei strain Shirota (LcS) has been shown to have potent anti-tumour and anti-metastatic effects on transplantable tumour cells and to suppress chemically-induced carcinogenesis in rodents. In particular, intrapleural (i.pl.) administration of LcS into tumour-bearing mice has been shown to effectively inhibit the growth of tumour cells in the thoracic cavity and to significantly prolong survival time. Also, i.pl. administration of LcS has been shown to induce the production of several cytokines, such as IFN-gamma, IL-1beta and TNF-alpha, in the thoracic cavity of mice, resulting in the inhibition of tumour growth and increased survival. On the other hand, oral administration of LcS has been shown to inhibit the growth of implantable tumour cells in rodents, and to restore the decreased mitogenic response of tumour-bearing mice. Administration of LcS has also been shown to inhibit chemically-induced bladder cancer in rodents. These findings suggest that treatment with LcS has the potential to ameliorate or prevent a variety of diseases through modulation of the host's immune system, specifically cellular immune responses.
干酪乳杆菌代田株（LcS）已被证明对可移植肿瘤细胞具有强大的抗肿瘤和抗转移作用，并能抑制啮齿动物的化学诱导致癌作用。特别是，向荷瘤小鼠胸膜腔内（i.pl.）注射LcS已被证明可有效抑制胸腔内肿瘤细胞的生长，并显著延长存活时间。此外，i.pl.注射LcS已被证明可在小鼠胸腔内诱导多种细胞因子的产生，如干扰素-γ、白细胞介素-1β和肿瘤坏死因子-α，从而抑制肿瘤生长并延长存活时间。另一方面，口服LcS已被证明可抑制啮齿动物体内可植入肿瘤细胞的生长，并恢复荷瘤小鼠降低的有丝分裂反应。LcS给药还被证明可抑制啮齿动物的化学诱导膀胱癌。这些发现表明，LcS治疗有可能通过调节宿主免疫系统，特别是细胞免疫反应，来改善或预防多种疾病。
